The European Commission has approved expanded indication for linagliptin in a wider range of adult Type 2 Diabetes (T2D) patients

INGELHEIM, Germany - Friday, October 26th 2012 [ME NewsWire]

(BUSINESS WIRE)-- For Non-U.S. and Non-U.K. Media

Boehringer Ingelheim and Eli Lilly and Companytoday announced that the European Commission has approved an expanded therapeutic indication for the DPP-4 inhibitor Trajenta® (linagliptin) to include use in combination with insulin in adults with Type 2 Diabetes.

"We are delighted that approval has been granted for the use of linagliptin as an add-on to insulin in adults with Type 2 Diabetes,” said Prof. Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim, "This expanded indication shows that linagliptin is an effective treatment for patients at various stages of Type 2 Diabetes.”

The approval means linagliptin is now indicated for use in combination with insulin with or without metformin, ... Read more »

Cost control drives gains in operating cash flow

BUSINESS WIRE / ME NewsWire - SHENZHEN, China - Friday, October 26th 2012 [ME NewsWire]

ZTE Corporation ("ZTE”) (H share stock code: 0763.HK / A share stock code: 000063.SZ), a publicly-listed global provider of telecommunications equipment and network solutions, today announced its financial results for the first three quarters ended September 30, 2012.

Based on PRC ASBEs, the company’s operating revenue amounted to RMB 60.7 billion, an increase by approximately 5% compared to same period a year earlier. Net loss attributable to share holders of the parent company amounted to RMB 1.7 billion, representing a year-on-year reverse of 259.1%. According to the company, during the reporting period, ZTE’s operating cash flow increased by over RMB 6 billion compared to the same period of last year. During the period, selling and administrative expenses decreased without impacting the company’s commitment to research and de ... Read more »